Best Management of Muscle Relaxation- Objective Monitoring

PHASE4CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

May 28, 2019

Primary Completion Date

January 31, 2020

Study Completion Date

March 31, 2020

Conditions
Residual Paralysis, Post Anesthesia
Interventions
COMBINATION_PRODUCT

Protocol for Management of Muscle Relaxation With Rocuronium Using Objective Monitoring and Reversal With Neostigmine or Sugammadex

The protocol includes specified appropriate rocuronium dosing and a valid pre-reversal assessment of the adductor pollicis response guides optimal neostigmine vs. sugammadex reversal.

Trial Locations (1)

98104

Harborview Medical Center, Seattle

All Listed Sponsors
lead

University of Washington

OTHER

NCT03958201 - Best Management of Muscle Relaxation- Objective Monitoring | Biotech Hunter | Biotech Hunter